Search Results - "Wachtell, K."

Risk prediction is improved by adding markers of subclinical organ damage to SCORE by Sehestedt, Thomas, Jeppesen, Jørgen, Hansen, Tine W., Wachtell, Kristian, Ibsen, Hans, Torp-Petersen, Christian, Hildebrandt, Per, Olsen, Michael H.

“…Aims It is unclear whether subclinical vascular damage adds significantly to Systemic Coronary Risk Evaluation (SCORE) risk stratification in healthy subjects…”
Get full text

[OP.7B.06] RELATIONSHIP OF INCIDENT ATRIAL FIBRILLATION TO THE ELECTROCARDIOGRAPHIC STRAIN PATTERN IN HYPERTENSIVE PATIENTS WITH ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY by Wachtell, K, Kjeldsen, S, Devereux, R, Okin, P

“…OBJECTIVE:Atrial fibrillation (AF) is strongly related to hypertension and to left ventricular hypertrophy (LVH), and both regression of ECG-LVH and…”
Get full text

[OP.4A.09] THE RELATIONSHIP OF ALL-CAUSE MORTALITY TO AVERAGE ON-TREATMENT SYSTOLIC BP IS RELATED TO BASELINE SYSTOLIC BP: IMPLICATIONS FOR INTERPRETATION OF THE SPRINT STUDY by Kjeldsen, S, Wachtell, K, Devereux, R, Okin, P

“…OBJECTIVE:The SPRINT study demonstrated that targeting systolic blood pressure (SBP) <120 mm Hg was associated with lower cardiovascular event and mortality…”
Get full text

Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension by Devereux, Richard B, Wachtell, Kristian, Gerdts, Eva, Boman, Kurt, Nieminen, Markku S, Papademetriou, Vasilios, Rokkedal, Jens, Harris, Katherine, Aurup, Peter, Dahlöf, Björn

“…CONTEXT Increased baseline left ventricular (LV) mass predicts cardiovascular (CV) complications of hypertension, but the relation between lower LV mass and…”
Get full text

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study by Wachtell, Kristian, Lehto, Mika, Gerdts, Eva, Olsen, Michael H, Hornestam, Björn, Dahlöf, Björn, Ibsen, Hans, Julius, Stevo, Kjeldsen, Sverre E, Lindholm, Lars H, Nieminen, Markku S, Devereux, Richard B

“…This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on…”
Get full text

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study by Ibsen, Hans, Olsen, Michael H, Wachtell, Kristian, Borch-Johnsen, Knut, Lindholm, Lars H, Mogensen, Carl Erik, Dahlöf, Björn, Devereux, Richard B, de Faire, Ulf, Fyhrquist, Frej, Julius, Stevo, Kjeldsen, Sverre E, Lederballe-Pedersen, Ole, Nieminen, Markku S, Omvik, Per, Oparil, Suzanne, Wan, Ying

“…Few data are available to clarify whether changes in albuminuria over time translate to changes in cardiovascular risk. The aim of the present study was to…”
Get full text

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial by Devereux, Richard B, Dahlöf, Björn, Gerdts, Eva, Boman, Kurt, Nieminen, Markku S, Papademetriou, Vasilios, Rokkedal, Jens, Harris, Katherine E, Edelman, Jonathan M, Wachtell, Kristian

“…An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to…”
Get full text

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation : The losartan intervention for end point reduction in hypertension (LIFE) study by WACHTELL, Kristian, HORNESTAM, Björn, KJELDSEN, Sverre E, LINDHOLM, Lars H, NIEMINEN, Markku S, ROKKEDAL, Jens, DEVEREUX, Richard B, LEHTO, Mika, SLOTWINER, David J, GERDTS, Eva, OLSEN, Michael H, AURUP, Peter, DAHLOF, Björn, IBSEN, Hans, JULIUS, Stevo

“…We assessed the impact of antihypertensive treatment in hypertensive patients with electrocardiographic (ECG) left ventricular (LV) hypertrophy and a history…”
Get full text

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study by Ibsen, Hans, Olsen, Michael H, Wachtell, Kristian, Borch-Johnsen, Knut, Lindholm, Lars H, Mogensen, Carl E, Dahlöf, Björn, Snapinn, Steven M, Wan, Ying, Lyle, Paulette A

“…OBJECTIVE:--Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes…”
Get full text

Impact of overweight and obesity on cardiac benefit of antihypertensive treatment by Gerdts, E, de Simone, G, Lund, B.P, Okin, P.M, Wachtell, K, Boman, K, Nieminen, M.S, Dahlöf, B, Devereux, R.B

“…Abstract Background and aims Increased body mass index (BMI) has been associated with increased cardiovascular morbidity and mortality in hypertension. Less is…”
Get full text

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers by Smink, PA, Hoekman, J, Grobbee, DE, Eijkemans, MJC, Parving, H-H, Persson, F, Ibsen, H, Lindholm, L, Wachtell, K, de Zeeuw, D, Heerspink, HJ Lambers

“…Introduction We recently developed and validated in existing trials a novel algorithm (PRE score) to predict long-term drug efficacy based on short-term…”
Get full text

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE Study by Olsen, Michael H, Wachtell, Kristian, Ibsen, Hans, Lindholm, Lars H, Dahlöf, Björn, Devereux, Richard B, Kjeldsen, Sverre E, Oikarinen, Lasse, Okin, Peter M

“…BACKGROUNDIn the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, reduced urine albumin/creatinine ratio (UACR) as well as regression…”
Get full text

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy by Ibsen, Hans, Wachtell, Kristian, Olsen, Michael H, Borch-Johnsen, Knut, Lindholm, Lars H, Mogensen, Carl Erik, Dahlöf, Björn, Devereux, Richard B, de Faire, Ulf, Fyhrquist, Frej, Julius, Stevo, Kjeldsen, Sverre E, Lederballe-Pedersen, Ole, Nieminen, Markku S, Omvik, Per, Oparil, Suzanne, Wan, Ying

“…OBJECTIVESTo examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive…”
Get full text

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study by Kizer, Jorge R, Dahlöf, Björn, Kjeldsen, Sverre E, Julius, Stevo, Beevers, Gareth, de Faire, Ulf, Fyhrquist, Frej, Ibsen, Hans, Kristianson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H, Nieminen, Markku S, Omvik, Per, Oparil, Suzanne, Wedel, Hans, Wachtell, Kristian, Edelman, Jonathan M, Snapinn, Steven M, Harris, Katherine E, Devereux, Richard B

“…The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan…”
Get full text

Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study by de Simone, G, Okin, P.M, Gerdts, E, Olsen, M.H, Wachtell, K, Hille, D.A, Dahlöf, B, Kjeldsen, S.E, Devereux, R.B

“…Abstract Background and aims Clusters of metabolic abnormalities resembling phenotypes of metabolic syndrome predicted outcome in the LIFE study, independently…”
Get full text

Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study by DE SIMONE, G, OLSEN, M. H, WACHTELL, K, HILLE, D. A, DAHLÖF, B, IBSEN, H, KJELDSEN, S. E, LYLE, P. A, DEVEREUX, R. B

“…The relation of metabolic syndrome (MetS) with cardiovascular outcome may be less evident when preclinical cardiovascular disease is present. We explored, in a…”
Get full text

Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: The LIFE study by Larstorp, A C K, Okin, P M, Devereux, R B, Olsen, M H, Ibsen, H, Dahlöf, B, Kjeldsen, S E, Wachtell, K

“…The predictive value of changes in the severity of electrocardiographic left ventricular hypertrophy (ECG-LVH) during antihypertensive therapy remains unclear…”
Get full text

Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study by Oikarinen, Lasse, Nieminen, Markku S, Viitasalo, Matti, Toivonen, Lauri, Wachtell, Kristian, Papademetriou, Vasilios, Jern, Sverker, Dahlöf, Björn, Devereux, Richard B, Okin, Peter M

“…OBJECTIVE In hypertensive patients, left ventricular hypertrophy (LVH) predicts increased mortality, in part due to an increased incidence of sudden death…”
Get full text

Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study by Gerdts, E, Okin, P.M, Omvik, P, Wachtell, K, Dahlöf, B, Hildebrandt, P, Nieminen, M.S, Devereux, R.B

“…Abstract Background and aim Diabetes is associated with left ventricular hypertrophy (LVH) and impaired systolic function in hypertensive patients, but less is…”
Get full text

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study by Ibsen, Hans, Wachtell, Kristian, Olsen, Michael H., Borch-JohnseN, Knut, Lindholm, Lars H., Mogensen, Carl Erik, Dahlöf, Björn

“…Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Studies have shown that albuminuria is…”
Get full text